Could Mainz Biomed's 33% revenue growth, 30% lower operating loss, and 15,000-patient partnership signal a bright future? With promising cancer detection tech and $8.1 target, this biotech is worth a closer look π $NIO $DRMA $GME $GME $PLTR
Mainz Biomed's 2024 results are impressive π₯ Revenue up 33%, losses down 30%. They're developing next-gen cancer tests and just raised $8M. Looking forward to their pipeline updates in 2025! $AAPL $GM $GME $GME $PLTR
Missed the $MYNZ train? Don't fret - the gains are just getting started. With $MYNZ at $3.97 and a target of $8.10, this is the perfect time to hop on board. Show those yachts who's boss! π #investing#stocks#canadianpride $GME $AAPL $HOOD
π $MYNZ is heating up! π₯ Don't miss the boat - this stock is undervalued and ready to soar. Grab $MYNZ before the gains roll in! π° $ORCL $INTC $CSCO
Saw the $MYNZ price jump - looks like a great opportunity to get in before it keeps climbing! As a Canadian software dev who loves tech, I'm bullish on their growth potential. #InvestmentTip#MobileApps#TechStock $SHOP $LULU $LSPD
#XAUUSD#Gold has now fallen back to around 2910 and quickly rebounded to around 2922.
We are focusing on whether it can break through the 2930 resistance zone.
If it cannot break through effectively, short positions can be arranged around 2930.
Why Europe is mired in slow growth:
"The European tax take from workers' wages in Germany, France, and Italy is over 50%. That means the state owns more of European workers' income than they do."
EU WORKERS = SLAVES OF THE STATE.
If MYNZ was trading at $10 today, youβd still buy.
So why not at $6?
Be early. ππ₯
$MSTR $FUBO #Painfession $HOLO $PLTR #MEAPY $SOFI $TSLA #BBMzansi
π From uncertainty around the macroeconomic environment to advancements in AI, @Nasdaqβs 6th Annual Global IR Issuer Pulse surfaces top IR priorities and challenges.
Discover survey findings based on data from over 800 corporate professionals globally: https://t.co/fwwIL9EkYi